Antimicrobial Susceptibility Testing Market Size & Growth Forecast 2027–2036, By Segments (Application, Product, End-use, Technique), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Antimicrobial Susceptibility Testing Market size was valued at USD 4.07 billion in 2026 and is anticipated to grow at a 4.85% CAGR from 2027 to 2036, surpassing USD 6.54 billion by 2036. The industry revenue for 2027 is assessed at USD 4.24 billion.

• Base Year Value (2026): USD 4.07 billion
• CAGR (2027-2036): 4.85%
• Forecast Year Value (2036): USD 6.54 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Antimicrobial Susceptibility Testing Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America holds a 49.08% share, supported by advanced laboratory infrastructure, high testing volumes, and routine integration of susceptibility testing in hospital care workflows.
  • Asia Pacific is growing at a 5.88% CAGR due to expanding laboratory capacity, improving diagnostic infrastructure, and increased focus on infectious disease management.

• Segment Momentum:

  • Manual Tests accounted for 55.93% of the market in 2026 due to their widespread use, established laboratory workflows, operational familiarity, and accessibility for routine microbiology testing.
  • Drug Development is growing fastest because pharmaceutical and research organizations increasingly rely on susceptibility testing to support antimicrobial evaluation, screening, validation, and pipeline development activities.

• Market Expansion Drivers:

  • Rising antimicrobial resistance cases increasing demand for rapid susceptibility testing solutions.
  • Expanding infectious disease drug development activities accelerating AST adoption in pharmaceutical research.
  • Growing integration of rapid diagnostic platforms supporting personalized antimicrobial treatment strategies.

• Leading Market Participants:

  Top players in the antimicrobial susceptibility testing market include Thermo Fisher Scientific Inc. (USA), Danaher Corporation (USA), Bio-Rad Laboratories, Inc. (USA), Becton, Dickinson and Company (USA), Merck KGaA (Germany), bioMérieux SA (France), Siemens Healthineers AG (Germany), Abbott Laboratories (USA), Bruker Corporation (USA), F. Hoffmann-La Roche Ltd (Switzerland).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 4.07 billion
  • 2027 Estimated Market Size: USD 4.24 billion.
  • Projected Market Size: USD 6.54 billion by 2036
  • Growth Forecasts: 4.85% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Susceptibility Testing (Application) | Manual Tests (Product) | Hospitals (End-use) | Disk Diffusion (Technique)
  • Emerging Opportunity Segment: Drug Development (Application) | Automated Instruments (Product) | Biotechnology & Pharmaceutical Companies (End-use) | Automated AST (Technique)

Market Growth Drivers and Industry Trends

Rising antimicrobial resistance cases increasing demand for rapid susceptibility testing solutions

Rising antimicrobial resistance cases will drive the antimicrobial susceptibility testing market growth by increasing the importance of identifying which antimicrobial agents are effective against specific pathogens. Rapid susceptibility testing can provide healthcare professionals with clinically relevant information to support more appropriate treatment selection and reduce reliance on ineffective antimicrobial therapies. The growing complexity of resistant infections also increases the need for testing methods that can generate actionable susceptibility information within clinically relevant timeframes.

Expanding infectious disease drug development activities accelerating AST adoption in pharmaceutical research

Expanding infectious disease drug development activities will propel the antimicrobial susceptibility testing market growth by increasing the use of AST methods during the evaluation of antimicrobial candidates. Pharmaceutical researchers require susceptibility data to assess the effectiveness of investigational compounds against relevant pathogens and to understand response patterns during drug development. AST can therefore support research workflows ranging from compound screening and characterization to the evaluation of antimicrobial activity across different infectious disease models.

Growing integration of rapid diagnostic platforms supporting personalized antimicrobial treatment strategies

Growing integration of rapid diagnostic platforms will boost the antimicrobial susceptibility testing market demand by enabling faster identification of pathogens and their response to available antimicrobial therapies. Combining rapid diagnostics with susceptibility testing can provide clinicians with more timely information for tailoring treatment to individual infection profiles. This approach supports more targeted antimicrobial selection and can help healthcare providers avoid unnecessary use of broad-spectrum therapies when pathogen-specific susceptibility information is available.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising antimicrobial resistance cases increasing demand for rapid susceptibility testing solutions	2.00%	High	North America, Asia Pacific	High	Near Term
Expanding infectious disease drug development activities accelerating AST adoption in pharmaceutical research	1.70%	Moderate	North America, Europe	High	Mid Term
Growing integration of rapid diagnostic platforms supporting personalized antimicrobial treatment strategies	1.40%	Moderate	Europe, Asia Pacific	Emerging	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

In the antimicrobial susceptibility testing market, North America accounted for a 49.08% share in 2026, underpinned by sophisticated clinical laboratory infrastructure, strong awareness of antimicrobial resistance, and widespread adoption of advanced diagnostic technologies. Healthcare providers increasingly rely on susceptibility testing to guide appropriate antibiotic selection and support more effective management of drug-resistant infections. The region's established microbiology capabilities, integration of automated laboratory systems, and emphasis on evidence-based antimicrobial stewardship are reinforcing demand. Continued technological advancement in rapid and automated testing is also improving laboratory efficiency and enabling clinicians to obtain actionable information more effectively.

Asia Pacific is experiencing the fastest growth, fueled by the rising burden of infectious diseases, increasing antimicrobial resistance concerns, and ongoing improvements in diagnostic healthcare infrastructure. Expanding hospital networks and laboratory capacity are creating greater opportunities for routine susceptibility testing, particularly as healthcare systems place stronger emphasis on accurate pathogen identification and responsible antibiotic use. Growing investments in automated diagnostics, laboratory modernization, and infection-control programs are further supporting adoption. Increased awareness among healthcare professionals regarding antimicrobial stewardship is also encouraging the integration of susceptibility testing into clinical decision-making across the region.

Key Country Insights

United States

Automated Stewardship Systems

U.S. antimicrobial susceptibility testing market is driven by hospital-based infection control programs and adoption of automated microbiology platforms. Clinical laboratories prioritize rapid pathogen identification and resistance profiling, supporting antibiotic stewardship initiatives across large healthcare systems and outpatient diagnostic networks.

Japan

Rapid Diagnostics Integration

Japan’s antimicrobial susceptibility testing market is influenced by hospital efficiency requirements and strong antimicrobial stewardship programs. Clinical laboratories focus on automation and precise resistance profiling, with increasing use of rapid diagnostic technologies to support optimized antibiotic selection in both acute and long-term care settings.

South Korea

Digital Microbiology Labs

South Korea’s antimicrobial susceptibility testing market benefits from digitally enabled hospital laboratories and strong adoption of automated diagnostic platforms. Integration with hospital information systems supports real-time reporting of resistance patterns, enabling clinicians to refine antibiotic prescribing practices across major medical centers.

Germany

Standardized Lab Automation

Germany’s antimicrobial susceptibility testing market is shaped by standardized laboratory practices and strong integration within hospital microbiology networks. Diagnostic institutions emphasize compliance with European guidelines and invest in automated systems to improve turnaround time and accuracy of resistance testing across clinical settings.

France

National Resistance Surveillance

France’s antimicrobial susceptibility testing market is supported by coordinated public health surveillance systems and hospital laboratory networks. Diagnostic practices emphasize standardized resistance monitoring and integration of microbiology data into national antimicrobial stewardship efforts across both inpatient and outpatient care environments.

Italy

Regional Lab Coordination

Italy’s antimicrobial susceptibility testing market relies on regional laboratory networks that support hospital diagnostic needs and infectious disease management. Laboratories increasingly adopt automated susceptibility testing systems to improve consistency and turnaround times, while strengthening coordination between clinical microbiology units and treating physicians.

Segment Leadership and Growth Trends

 

Application Segment Analysis: Susceptibility Testing (Largest Segment) vs Drug Development (Fastest-Growing Segment)

In the antimicrobial susceptibility testing market, susceptibility testing held the largest share in 2026, reflecting its fundamental role in guiding appropriate antimicrobial treatment decisions. These tests enable healthcare professionals to determine how effectively specific microorganisms respond to available antimicrobial agents, supporting more informed therapy selection and helping address the growing challenge of antimicrobial resistance. Their importance extends across clinical microbiology laboratories, hospitals, and diagnostic settings where timely identification of effective treatment options is essential. Increasing attention to antimicrobial stewardship and the need to reduce inappropriate antibiotic use continue to reinforce demand for susceptibility testing.

Drug development is the fastest-growing application segment, supported by the increasing need to evaluate antimicrobial candidates against resistant pathogens during research and development activities. Susceptibility testing provides critical evidence on the effectiveness of emerging compounds and helps researchers characterize pathogen responses during the development process. Rising scientific focus on novel antimicrobial therapies, particularly those capable of addressing resistant infections, is increasing the importance of testing platforms within pharmaceutical and research workflows. Advances in laboratory methods and growing investment in antimicrobial discovery are consequently creating stronger opportunities for this application.

Product Segment Analysis: Manual Tests (Largest Segment) vs Automated Instruments (Fastest-Growing Segment)

Manual tests accounted for the largest share of the antimicrobial susceptibility testing market in 2026, supported by their broad applicability, established laboratory workflows, and accessibility across diverse testing environments. Conventional methods remain important because they can be implemented without highly complex infrastructure and provide laboratories with practical approaches for assessing antimicrobial response. Their continued use is particularly relevant in settings where cost considerations, established operating procedures, and flexibility in test selection influence purchasing decisions. The longstanding familiarity of laboratory personnel with manual susceptibility testing also contributes to its continued market presence.

Automated instruments are experiencing the fastest growth as laboratories increasingly prioritize rapid, standardized, and efficient antimicrobial susceptibility testing. Automated systems can streamline specimen processing, reduce manual intervention, and support consistent interpretation of test results, making them valuable for laboratories managing substantial testing workloads. Their integration with laboratory information systems and broader diagnostic automation also improves workflow coordination and supports faster clinical decision-making. As healthcare facilities place greater emphasis on operational efficiency, antimicrobial stewardship, and timely detection of resistant organisms, automated instruments are gaining increasing relevance.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Application	Drug Development, Susceptibility Testing, Others	Susceptibility Testing	Drug Development
Product	Manual Tests, Automated Instruments, Consumables & Media	Manual Tests	Automated Instruments
End-use	Hospitals, Diagnostic Laboratories, Biotechnology & Pharmaceutical Companies, Others	Hospitals	Biotechnology & Pharmaceutical Companies
Technique	Automated AST, Etest Method, Dilution, Disk Diffusion, Others	Disk Diffusion	Automated AST

Competitive Landscape and Market Positioning

Major players in the antimicrobial susceptibility testing market:

1. Thermo Fisher Scientific Inc. (USA)

2. Danaher Corporation (USA)

3. Bio-Rad Laboratories Inc. (USA)

4. Becton Dickinson and Company (USA)

5. Merck KGaA (Germany)

6. bioMérieux SA (France)

7. Siemens Healthineers AG (Germany)

8. Abbott Laboratories (USA)

9. Bruker Corporation (USA)

10. F. Hoffmann-La Roche Ltd (Switzerland)

The antimicrobial susceptibility testing market is evolving with improved diagnostic accuracy and faster testing methodologies. Innovation in testing platforms is enabling more efficient clinical decision-making. Collaborative research efforts are enhancing laboratory capabilities and expanding technological reach. Ongoing development is strengthening resistance detection and improving healthcare response systems.

Industry Development/News

Company Name	Date	Key Development
iFAST Diagnostics	May-26	iFAST Diagnostics secured £5 million in funding, including non-dilutive support from Innovate UK. This capital injection is earmarked to accelerate the company's UK rollout, secure EU regulatory approval, and advance its clinical and regulatory programs for FDA clearance, scaling its rapid antimicrobial susceptibility testing platform capable of delivering results in under three hours.
Astorg; Thermo Fisher Scientific	Apr-26	Astorg entered a definitive agreement to acquire Thermo Fisher Scientific’s global microbiology business for approximately $1.08 billion. The unit, which focuses on antimicrobial susceptibility testing and culture media, will operate as an independent, private platform. This divestiture allows Thermo Fisher to optimize its portfolio while enabling Astorg to drive growth and operational performance in the specialized diagnostics sector.
InnotiveDx	Nov-25	InnotiveDx received a £1 million grant from the Pathways to Antimicrobial Clinical Efficacy (PACE) initiative to further develop its rapid urinary tract infection diagnostic system. The funding supports the validation of automated prototypes that provide comprehensive bacterial identification and antimicrobial susceptibility results in under 60 minutes, addressing critical needs in point-of-care antimicrobial stewardship.
bioMérieux; Vall d'Hebron	Feb-25	bioMérieux formed a strategic research partnership with the Vall d'Hebron Barcelona Hospital Campus to advance innovation in infectious disease diagnostics. The collaboration focuses on laboratory automation, data surveillance, and clinical research, directly supporting the development and optimization of high-performance tools for microbiology and antimicrobial susceptibility testing within high-complexity hospital environments.
bioMérieux	Jul-24	bioMérieux received U.S. FDA 510(k) clearance for its Vitek Reveal AST System. This authorization enables the direct, rapid determination of antimicrobial susceptibility from positive blood cultures, significantly reducing the turnaround time for critical infectious disease diagnostics and improving therapeutic decision-making for patients suffering from severe infections and sepsis.
Bruker	Apr-24	Bruker expanded its clinical microbiology portfolio with the integration of advanced solutions for microbial identification and antimicrobial susceptibility testing. By broadening its range of high-throughput diagnostic tools, the company has strengthened its competitive positioning in the infectious disease testing market, facilitating earlier diagnosis and more targeted treatment selection for sepsis and other multi-drug resistant infections.